A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This is a first-in-human (FIH), randomized, placebo-controlled, double-blind, single ascending dose (SAD) study to assess the safety and tolerability of VIS954, a monoclonal antibody, in healthy adult male and female participants.
Epistemonikos ID: cd97d28b877d2fbe3ddd3ec835fb368dbae89005
First added on: May 15, 2024